RSS   Newsletter   Contact   Advertise with us

Sinovac says coronavirus vaccine induced immune response in over 90% of volunteers

Christian Fernsby ▼ | June 15, 2020
Sinovac Biotech Ltd. announced positive preliminary results of phase I/II clinical trial for the company’s COVID-19 vaccine candidate, named CoronaVac, which showed favorable immunogenicity and safety profiles.
Vaccine   Sinovac is collaborating with Instituto Butantan in Brazil
The phase I/II clinical trials were designed as randomized, double-blind and placebo-controlled studies. In total, 743 healthy volunteers, aged from 18 to 59 years old, enrolled in the trials.

Topics: sinovac coronavirus vaccine

Of those, 143 volunteers are in phase I and 600 volunteers are in phase II. There have been no severe adverse event reported in either the phase I or phase II trials. The phase II clinical trial results show that the vaccine induces neutralizing antibodies 14 days after the vaccination with a 0,14 day schedule.

The neutralizing antibody seroconversion rate is above 90%, which concludes the vaccine candidate can induce positive immune response.

The Company expects to submit a phase II clinical study report and a phase III clinical study protocol to China’s National Medical Products Administration (NMPA) in the near future and commence application of phase III clinical trials outside of China.

Sinovac is collaborating with Instituto Butantan in Brazil to prepare and conduct a phase III clinical study. The Company expects to share the full data on clinical trials with the public through academic publications.

Sinovac’s development of a vaccine against COVID-19 began in January 2020 in partnership with leading academic research institutes in China. The Company received approval from China’s NMPA on April 13 to conduct phase I/II studies on its inactivated vaccine candidate against COVID-19 in China.